Taliglucerase alfa (Elelyso)

Elelyso (taliglucerase alfa) is covered only for Type 1 Gaucher disease in patients aged ≥4 years (not for patients <4 years or off‑label indications) when diagnosis is confirmed by deficient β‑glucocerebrosidase activity or GBA molecular testing and it is prescribed by or in consultation with an appropriate specialist. Authorization is limited to 1 year, dosing must be 60 U/kg IV no more frequently than every 2 weeks, and documentation of age, diagnostic test results, specialist involvement, and dosing/administration records is required (absence of these is grounds for non‑approval).

"Elelyso is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.